Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 31, 2024
Event: Entry into a Material Definitive Agreement (Collaboration and License Agreement) with Takeda Pharmaceuticals USA, Inc. for the development and commercialization of the rusfertide product candidate and other second-generation injectable hepcidin mimetic compounds.
Key Financial Metrics and Deal Terms
This filing details a strategic partnership rather than historical financial performance. Key financial terms include:
- Upfront Payment: $300 million payable by Takeda within 30 days of the Effective Date (subject to HSR clearance).
- Profit Sharing (U.S.): 50% to Protagonist and 50% to Takeda on operating profits and losses in the United States ("Profit-Share Territory").
- Royalties (Ex-U.S.): Tiered royalties of 10% – 17% on net sales in the "Takeda Territory" (all countries outside the U.S.).
- Milestone Payments:
- Up to $330 million if the Company remains in the 50:50 profit-sharing arrangement.
- Up to $975 million if the Company exercises the Full Opt-out Right.
- Opt-out Payments: If the Company exercises the Full Opt-out Right during the Initial Opt-out Period, it receives a $200 million payment upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera.
Material Changes and Operational Structure
The agreement establishes a new operational framework for the Company's lead asset, rusfertide:
- Development Leadership: Protagonist leads and funds the ongoing Phase 3 VERIFY program for polycythemia vera. Takeda leads pre-commercialization activities in the U.S. and all activities globally outside the U.S.
- Commercialization: Takeda leads global commercialization. Protagonist retains an option to co-detail in the U.S.
- Cost Sharing: Costs in the U.S. are shared; Takeda bears all costs for the Takeda Territory.
- Exclusivity: Takeda receives an exclusive license in the Takeda Territory and a co-exclusive license in the U.S. Neither party may develop competing injectable hepcidin mimetic products beyond specified stages.
Guidance, Risks, and Contingencies
Contingencies: The agreement becomes effective only upon receipt of clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The full text of the agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2024.
Termination Rights: Takeda may terminate the agreement for convenience following the receipt of Phase 3 data for the VERIFY Program, the third anniversary of the Effective Date, or upon certain adverse clinical events. Either party may terminate for material breach or insolvency.
Opt-out Rights: Protagonist holds the right to opt-out of the U.S. profit-sharing arrangement (Full Opt-out) during a 90-day window beginning 120 days after the filing of the New Drug Application (NDA) for rusfertide. Partial opt-outs are available for other licensed products.
Investor Verification Checklist
- Confirm the receipt of HSR clearance to validate the Effective Date and the timing of the $300 million upfront payment.
- Monitor the progress of the Phase 3 VERIFY program, as Phase 3 data receipt triggers a Takeda termination right.
- Track the filing date of the NDA for rusfertide to determine the start of the Initial Opt-out Period.
- Review the upcoming Form 10-Q (Q1 2024) for the full text of the Collaboration Agreement and any specific accounting treatment for the upfront payment.
- Assess the impact of the 50:50 profit-sharing model on future cash flow volatility compared to a royalty-only model.